XZP-5209

N/A

Report date: 2022/10/25 13:05:02

Base Information

Drug NameXZP-5209
Drug Alias NameXZP-5209
ClassificationOther
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsReceptor protein-tyrosine kinase erbB-4 antagonistsEGFR T790M inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4EGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A